Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Analysts Up-Beat On Xencor's XmAB5871 Despite Phase II 'Placebo Hiccup' in SLE

Executive Summary

Analysts shrugged off mixed topline data from a Phase II study showing Xencor’s lead compound XmAb5871 missed its primary endpoint in systemic lupus erythematosus (SLE), blaming the miss on the number of patients dropping out of the placebo arm of the trial.  

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123966

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel